Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 2 SPEC. ISS., 2006, Pages 141-151

  Canales, Benjamin K ^a   Li, Yingming ^a   Thompson, Melissa G ^b   Gleason, Joseph M ^a   Chen, Zhi ^c   Malaeb, Bahaa ^a   Corey, David R ^c   Herbert, Brittney Shea ^b,d   Shay, Jerry W ^b   Koeneman, Kenneth S ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Docetaxel; Gene therapy; Oligonucleotide; Prostate cancer; Telomerase; Telomerase inhibition

Indexed keywords

ANDROGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOCETAXEL; EOSIN; GRN 163; HEMATOXYLIN; ISIS 125628; ISIS 24691; OLIGONUCLEOTIDE; PROSTATE SPECIFIC ANTIGEN; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TUMOR GROWTH; VIRUS REPLICATION;

EID: 33644762771     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.003     Document Type: Conference Paper

References (74)

1. L. Hayfick, P.S. Moorhead The limited in vitro lifetime of human diploid cell strains Exp Cell Res 25 1961 585 621
2. J.D. Watson Origin of concatemeric T7 DNA Nat New Biol 239 1972 197 201
3. A.M. Olovnikov A theory of marginotomy The incomplete copying of template margin in enzymatic synthesis of polynucleotides and the biological significance of the phenomenon J Theor Biol 41 1973 181 190
4. K.E. Huffman, S.D. Levene, V.M. Tesmer Telomere shortening is proportional to the size of the G-rich telomeric 3′-overhang J Biol Chem 275 2000 19719 19722
5. C.B. Harley, A.B. Futcher, C.W. Greider Telomeres shorten during aging of human fibroblasts Nature 345 1990 458 460
6. N.D. Hastie, M. Dempster, M.G. Dunlop Telomere reduction in human colorectal carcinoma and with aging Nature 346 1990 866 868
7. C.M. Counter, H.W. Hirte, S. Bachetti Telomerase activity in human ovarian carcinoma Proc Natl Acad Sci USA 91 1994 2900 2904
8. R.K. Moyzis, J.D. Buckingham, L.S. Cram A highly conserved repetitive DNA sequence, (TTAGGG)n, present at telomeres of human chromosomes Proc Natl Acad Sci USA 85 1988 6622 6626
9. V.L. Makarov, Y. Hirose, J.P. Langmore Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening Cell 88 1997 657 666
10. B. Van Steensel, A. Smogorzewska, T. de Lange TRF2 protects human telomeres from end-to-end fusions Cell 92 1998 401 413
11. J.D. Griffith, L. Comeau, S. Rosenfield Mammalian telomeres end in a large duplex loop Cell 97 1999 503 514
12. A. Smogorzewska, B. van Steensel, A. Bianchi Control of human telomere length by TRF1 and TRF2 Mol Cell Biol 20 2000 1659 1668
13. C.J. Sherr, F. McCormick The RB and p53 pathways in cancer Cancer Cell 2 2002 103 112
14. A. Smogorzewska, T. de Lange Different telomere damage signaling pathways in human and mouse cells EMBO J 21 2002 4338 4348
15. J.W. Shay, W.E. Wright Telomerase A target for cancer therapeutics Cancer Cell 2 2002 257 265
16. H.J. Cooke, B.A. Smith Variability at the telomeres of the human X/Y pseudoautosomal region Cold Spring Harb Symp Quant Biol 51 1986 213 219
17. C.B. Harley Telomere loss Mitotic clock or genetic time bomb? Mutat Res 256 1991 271 282
18. N.W. Kim, M.A. Pietyszek, K.R. Prowse Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2020
19. J.W. Shay, S. Bacchetti A survey of telomerase activity in human cancer Eur J Cancer 5 1997 787 791
20. J. Feng, W.D. Funk, S.-S. Wang The RNA component of human telomerase Science 269 1995 1236 1241
21. T.M. Nakamura, G.B. Morin, K.B. Chapman Telomerase catalytic subunit homologs from fission yeast and human Science 277 1997 955 959
22. M. Meyerson, C.M. Counter, E.N. Eaton hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization Cell 90 1997 785 795
23. L. Harrington, T. McPhail, V. Mar Human telomerase contains evolutionarily conserved catalytic and structural subunits Genes Dev 11 1997 3109 3115
24. A.G. Bodnar, M. Ouellette, M. Frolkis Extension of life-span by introduction of telomerase into normal human cells Science 279 1998 349 352
25. C.P. Morales, S.E. Holt, M. Ouellette Absence of cancer-associated changes in human fibroblasts immortalized with telomerase Nat Genet 21 1999 115 118
26. C.B. Harley Telomerase is not an oncogene Oncogene 21 2002 494 502
27. W.C. Hahn, C.M. Counter, A.S. Lundberg Creation of human tumour cells with defined genetic elements Nature 400 1999 464 468
28. B.S. Herbert, A.E. Pitts, S.I. Baker Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death Proc Natl Acad Sci USA 96 1999 14276 14281
29. X.L. Zhang, V. Mar, W. Zhou Telomere shortening and apoptosis in telomerase-inhibited human tumour cells Genes Dev 13 1999 2388 2399
30. P. Nilsson, C. Mehle, K. Remes Telomerase activity in vivo in human malignant hematopoietic cells Oncogene 9 1994 3043 3048
31. J.W. Shay, Y. Zou, E. Hiyama Telomerase and cancer Hum Mol Genet 10 2001 677 685
32. L.A. Langford, M.A. Piatyszek, R. Xu Telomerase activity in human brain tumors Lancet 346 1995 1267 1268
33. T. de Lange Activation of telomerase in human tumor Proc Natl Acad Sci USA 91 1994 2882 2885
34. Y. Lin, H. Uemura, K. Fujinami Telomerase activity in primary prostate cancer J Urol 157 1997 1161 1165
35. Y. Lin, H. Uemura, K. Fujinami Detection of telomerase activity in prostate needle-biopsy samples Prostate 36 1998 121 128
36. W. Zhang, L.R. Kapusta, J.M. Slingerland Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium Cancer Res 58 1998 619 622
37. B.V. Kallakury, V.S. Bhaskar, T.P. Brien Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas Diagn Mol Pathol 6 1997 192 198
38. C. Takahashi, I. Miyagawa, S. Kumano Detection of telomerase activity in prostate cancer by needle biopsy Eur Urol 32 1997 494 498
39. H.J. Sommerfeld, A.K. Meeker, M.A. Piatyszek Telomerase activity A prevalent marker of malignant human prostate tissue Cancer Res 56 1996 218 222
40. B. Wullich, V. Rohde, B. Oehlenschlager Focal intratumoral heterogeneity for telomerase activity in human prostate cancer J Urol 161 1999 1997 2001
41. K. Koenenman, C.X. Pan, J.K. Jin Telomerase activity, telomere length and DNA ploidy in prostatic intraepithelial neoplasia (PIN) J Urol 160 1998 1533 1539
42. K. Damm, U. Hemmann, P. Garin-Chesa A highly selective telomerase inhibitor limiting human cancer cell proliferation EMBO J 20 2001 6958 6968
43. J.W. Shay, W.E. Wright Mechanism-based combination telomerase inhibition therapy Cancer Cell 7 2005 1 2
44. N.R. Forsyth, W.E. Wright, J.W. Shay Telomerase and differentiation in multicellular organisms Turn it off, turn it on, and turn it off again Differentiation 69 2002 188 197
45. N. Mahmud, S.M. Devine, K.P. Weller The relative quiescence of hematopoietic stem cells in nonhuman primates Blood 97 2001 3061 3068
46. M.M. Kim, M.A. Rivera, I.L. Botchkina A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation Proc Natl Acad Sci USA 98 2001 7982 7987
47. S. Koga, S. Hirohata, Y. Kondo FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo Anticancer Res 21 2001 1937 1943
48. J. Gu, M. Andreff, J.A. Roth hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity Gene Ther 9 2002 30 37
49. R.H. Vonderheide Telomerase as a universal tumor-associated antigen for cancer immunotherapy Oncogene 21 2002 674 679
50. I. Naasani, F. Oh-Hashi, T. Oh-Hara Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo Cancer Res 63 2003 824 830
51. D. Sun, B. Thompson, B.E. Cathers Inhibition of human telomerase by a G-quadruplex-interactive compound J Med Chem 40 1997 2113 2116
52. C. Strahl, E.H. Blackburn Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines Mol Cell Biol 16 1996 53 65
53. Y. Yokoyama, T. Takahashi, A. Shinohara Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells Cancer Res 58 1998 5406 5410
54. D.R. Corey Telomerase inhibition, oligonucleotides, and clinical trials Oncogene 21 2002 631 637
55. B.S. Herbert, K. Pongracz, J.W. Shay Oligonucleotide N3′-P5′ phosphoramidates as efficient telomerase inhibitors Oncogene 21 2002 638 642
56. B.F. Baker, B.P. Monia Novel mechanisms for antisense-mediated regulation of gene expression Biochim Biophys Acta 1489 1999 3 18
57. B. Jansen, U. Zangemeister-Wittke Antisense therapy for cancer the time of truth Lancet Oncol 3 2002 672 682
58. D.R. Corey Telomerase An unusual target for cytotoxic agents Chem Res Toxicol 13 2000 957 960
59. R.S. Geary, R.Z. Yu, A.A. Levin Drug properties of second-generation antisense oligonucleotides How do they measure up to their predecessors? Curr Opin Investig Drugs 2 2001 1444 1449
60. Z. Chen, K. Koeneman, D.R. Corey Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells Cancer Res 63 2003 5917 5925
61. H. Inoue, Y. Hayase, A. Imura Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides Nucleic Acids Res 15 1987 6131 6148
62. B.P. Monia, E.A. Lesnik, C. Gonzalez Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression J Biol Chem 268 1993 14514 14522
63. R.A. McKay, L.J. Miraglia, L.L. Cummins Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression J Biol Chem 274 1999 1715 1722
64. B.F. Baker, S.S. Lot, T.P. Condon 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells J Biol Chem 272 1997 11994 12000
65. S.P. Henry, K. Stecker, D. Brooks Chemically modified oligonucleotides exhibit decreased immune stimulation in mice J Pharmacol Exp Ther 292 2000 468 479
66. J.A. McCaffrey, S. Hilton, M. Mazumdar Phase II trial of docetaxel in-patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 15 1997 1853 1857
67. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
68. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
69. L.W. Chung, C.L. Hsieh, A. Law New targets for therapy in prostate cancer Modulation of stromal-epithelial interactions Urology 62 2003 44 54
70. H. Kanamaru, O. Yoshida Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay Urol Res 17 1989 259 264
71. M.M. Ouellette, M. Liao, B. Herbert Subsenescent telomere lengths in fibroblasts immortalized by limiting amounts of telomerase J Biol Chem 275 2000 10072 10076
72. Y. Li, T. Okegawa, D.P. Lombardi Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents J Urol 167 2002 339 346
73. X. Zhang, A.S. Multani, J.H. Zhou Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells Cancer Res 63 2003 760 765
74. S. Li, J. Crothers, C.M. Haqq Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA J Biol Chem 280 2005 23709 23717